Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 56

1.

Evaluation of Health-Related Quality of Life among Patients with Cervical Cancer in Indonesia.

Endarti D, Riewpaiboon A, Thavorncharoensap M, Praditsitthikorn N, Hutubessy R, Kristina SA.

Asian Pac J Cancer Prev. 2015;16(8):3345-50.

2.

Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.

Jauregui B, Garcia AG, Bess Janusz C, Blau J, Munier A, Atherly D, Mvundura M, Hajjeh R, Lopman B, Clark AD, Baxter L, Hutubessy R, de Quadros C, Andrus JK.

Vaccine. 2015 May 7;33 Suppl 1:A28-33. doi: 10.1016/j.vaccine.2014.10.090.

PMID:
25919170
3.

Estimating costs of care for meningitis infections in low- and middle-income countries.

Portnoy A, Jit M, Lauer J, Blommaert A, Ozawa S, Stack M, Murray J, Hutubessy R.

Vaccine. 2015 May 7;33 Suppl 1:A240-7. doi: 10.1016/j.vaccine.2014.11.061.

PMID:
25919168
4.

Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national Expanded Programme on Immunization.

Jit M, Dang TT, Friberg I, Hoang VM, Pham Huy TK, Walker N, Nguyen VC, Tran ND, Toda K, Hutubessy R, Fox K, Nguyen TH.

Vaccine. 2015 May 7;33 Suppl 1:A233-9. doi: 10.1016/j.vaccine.2014.12.017.

5.

Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study.

van der Putten IM, Evers SM, Deogaonkar R, Jit M, Hutubessy RC.

BMC Public Health. 2015 Apr 10;15:356. doi: 10.1186/s12889-015-1638-0.

6.

Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".

Newall AT, Jit M, Hutubessy R.

Pharmacoeconomics. 2014 Dec;32(12):1247. doi: 10.1007/s40273-014-0232-0. No abstract available.

PMID:
25374292
7.

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.

Jit M, Brisson M, Portnoy A, Hutubessy R.

Lancet Glob Health. 2014 Jul;2(7):e406-14. doi: 10.1016/S2214-109X(14)70237-2. Epub 2014 Jun 9.

8.

Reassessing the value of vaccines.

Bärnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, Constenla D, Driessen J, Edmunds J, Evans D, Griffiths U, Hansen P, Hashmani FN, Hutubessy R, Jamison DT, Jha P, Jit M, Johnson H, Laxminarayan R, Lee BY, Mhatre S, Mills A, Nordström A, Ozawa S, Prosser L, Silver K, Benn CS, Standaert B, Walker D.

Lancet Glob Health. 2014 May;2(5):e251-2. doi: 10.1016/S2214-109X(13)70170-0. Epub 2014 Apr 23. No abstract available.

9.

Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.

Levin A, Wang SA, Levin C, Tsu V, Hutubessy R.

PLoS One. 2014 Jun 26;9(6):e101114. doi: 10.1371/journal.pone.0101114. eCollection 2014.

10.

Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.

Newall AT, Jit M, Hutubessy R.

Pharmacoeconomics. 2014 Jun;32(6):525-31. doi: 10.1007/s40273-014-0162-x.

PMID:
24791735
11.

Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation.

Kotsopoulos N, Connolly MP, Postma MJ, Hutubessy RC.

Vaccine. 2013 Nov 4;31(46):5430-4. doi: 10.1016/j.vaccine.2013.09.002. Epub 2013 Sep 18.

PMID:
24055088
12.

Comparing sociocultural features of cholera in three endemic African settings.

Schaetti C, Sundaram N, Merten S, Ali SM, Nyambedha EO, Lapika B, Chaignat CL, Hutubessy R, Weiss MG.

BMC Med. 2013 Sep 18;11:206. doi: 10.1186/1741-7015-11-206.

13.

Sociocultural determinants of anticipated vaccine acceptance for acute watery diarrhea in early childhood in Katanga Province, Democratic Republic of Congo.

Merten S, Schaetti C, Manianga C, Lapika B, Hutubessy R, Chaignat CL, Weiss M.

Am J Trop Med Hyg. 2013 Sep;89(3):419-25. doi: 10.4269/ajtmh.12-0643. Epub 2013 Jul 22.

14.

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.

Fesenfeld M, Hutubessy R, Jit M.

Vaccine. 2013 Aug 20;31(37):3786-804. doi: 10.1016/j.vaccine.2013.06.060. Epub 2013 Jul 3. Review.

PMID:
23830973
15.

Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.

Ott JJ, Klein Breteler J, Tam JS, Hutubessy RC, Jit M, de Boer MR.

Hum Vaccin Immunother. 2013 Jul;9(7):1500-11. doi: 10.4161/hv.24704. Epub 2013 May 31. Review.

16.

Distinguishing social and cultural features of cholera in urban and rural areas of Western Kenya: Implications for public health.

Nyambedha EO, Sundaram N, Schaetti C, Akeyo L, Chaignat CL, Hutubessy R, Weiss MG.

Glob Public Health. 2013;8(5):534-51. doi: 10.1080/17441692.2013.787107. Epub 2013 May 14.

PMID:
23672503
17.

Q&A--Economic analyses for vaccine introduction decisions in low- and middle- income countries.

Hutubessy R.

BMC Med. 2013 Mar 14;11:71. doi: 10.1186/1741-7015-11-71. No abstract available.

18.

Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts.

Jit M, Levin C, Brisson M, Levin A, Resch S, Berkhof J, Kim J, Hutubessy R.

BMC Med. 2013 Jan 30;11:23. doi: 10.1186/1741-7015-11-23.

19.

Local perceptions of cholera and anticipated vaccine acceptance in Katanga province, Democratic Republic of Congo.

Merten S, Schaetti C, Manianga C, Lapika B, Chaignat CL, Hutubessy R, Weiss MG.

BMC Public Health. 2013 Jan 22;13:60. doi: 10.1186/1471-2458-13-60.

20.

Decision-making on malaria vaccine introduction: the role of cost-effectiveness analyses.

Moorthy VS, Hutubessy R, Newman RD, Hombach J.

Bull World Health Organ. 2012 Nov 1;90(11):864-6. doi: 10.2471/BLT.12.107482. Epub 2012 Sep 19. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk